We further demonstrated that at MDS diagnosis 47% (7/15) of AML-transforming patients showed RUNX1 mutations, significantly more frequent in AML-transforming compared to non-transforming patients. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.